Drug Development Pipeline

Dyve has conducted a broad set of studies that demonstrate superior efficacy when compared to oral and injectable delivery routes.

Dyve uses existing drugs with proven safety and efficacy to enable an efficient use of resources and fast development timelines while mitigating drug development and investor risk.

Dyve Biosciences has a robust patent portfolio with proven efficacy in 300+ patients across 10+ indications.

 


DYV-700 – Gout

Gout is a type of arthritis characterized by the formation of sodium urate crystals in the joint space, causing intense pain typically lasting 48-96 hours. Gout afflicts nearly 2-4% of the US population (10M+), with prevalence ranging as high as 10% in other countries. It is also one of the fastest growing therapeutic areas driven by its association with maladies such as diabetes and obesity. The vast majority of available treatments focus on chronic management, and there is a lack of effective options to alleviate the extreme pain subjects experience within the first few days of an acute gout attack. The pain of an acute gout attack can be debilitating, often leading to emergency room visits, hospital admissions, and missed days of work. Rapid reduction of this pain is a critical step in reducing the direct and indirect costs associated with gout. Through rapid delivery of an alkalizing agent to solubilize the sodium urate, Dyve’s technology brought pain relief to a high percentage of gout sufferers as early as 15 minutes after applying treatment.

“We are thrilled that a high percentage of patients had immediate pain relief, as early as 15 minutes after applying treatment. This could prove to be a major advancement for those suffering from gout, given the current treatment options available, which can take days to provide relief.”

Smitha Reddy, M.D., Principal Investigator, Arthritis Care and Research Center

DYV-600 – Melasma

Melasma is a hyperpigmentation disorder often associated with UV exposure, oral contraceptives, and pregnancy. Women of color and pregnant women are particularly susceptible, with 50-70% of post-partum women developing melasma. Melasma is caused by the hyperactivity of melanocytes, which produces blotches of pigmentation, typically on the cheeks and forehead. Severe discoloration from this condition has been shown to negatively affect an individual’s self-esteem and quality of life. Melanocytes are found deep within the skin, making the disorder difficult to treat. Current treatment options are invasive, ineffective, or have risks involved with long-term use. Dyve’s technology unlocks a known active’s potential, delivering it deep into the skin resulting in a significant and fast reduction in pigmentation. The results achieved by Dyve’s technology meet or exceed those obtained by other more invasive or risk-inducing treatment options.

“Our human proof-of-concept trial demonstrates how we can modulate our technology to optimize transdermal drug delivery and offer patients an effective option to injections, oral drugs, or ineffective topicals. We believe this has the potential of being a game changer in the treatment of hyperpigmentation.” 

Ryan Beal, MD, Dyve CEO